Receptor Conformations Involved in Dopamine D2L Receptor Functional Selectivity Induced by Selected Transmembrane-5 Serine Mutations by Fowler, J. C. et al.
Receptor Conformations Involved in Dopamine D2L Receptor
Functional Selectivity Induced by Selected Transmembrane-5
Serine Mutations□S
J. Corey Fowler, Supriyo Bhattacharya, Jonathan D. Urban, Nagarajan Vaidehi,
and Richard B. Mailman
Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey Pennsylvania (R.B.M.); Division of
Medicinal Chemistry and Toxicology Curriculum, University of North Carolina School of Medicine, Chapel Hill, North Carolina
(J.C.F., J.D.U., R.B.M.); and Beckman Research Institute at City of Hope Medical Center, Duarte, California (S.B., N.V.)
Received September 1, 2011; accepted March 13, 2012
ABSTRACT
Although functional selectivity is now widely accepted, the
molecular basis is poorly understood. We have studied how
aspects of transmembrane region 5 (TM5) of the dopamine D2L
receptor interacts with three rationally selected rigid ligands
(dihydrexidine, dinapsoline, and dinoxyline) and the reference
compounds dopamine and quinpirole. As was expected from
homology modeling, mutation of three TM5 serine residues to
alanine (S5.42A, S5.43A, S5.46A) had little effect on antagonist
affinity. All three mutations decreased the affinity of the agonist
ligands to different degrees, S5.46A being somewhat less af-
fected. Four functions [adenylate cyclase (AC), extracellular
signal-regulated kinase 1/2 phosphorylation (MAPK), arachi-
donic acid release (AA), and guanosine 5-O-(3-thio)triphos-
phate binding (GTPS)] were assessed. The intrinsic activity (IA)
of quinpirole was unaffected by any of the mutations, whereas
S5.42A and S5.46A mutations abolished the activity of dopa-
mine and the three rigid ligands, although dihydrexidine re-
tained IA at MAPK function only with S5.42A. Remarkably,
S5.43A did not markedly affect IA for AC and MAPK for any of
the ligands and eliminated AA activity for dinapsoline and di-
hydrexidine but not dinoxyline. These data suggest that this
mutation did not disrupt the overall conformation or signaling
ability of the mutant receptors but differentially affected ligand
activation. Computational studies indicate that these D2 ago-
nists stabilize multiple receptor conformations. This has led to
models showing the stabilized conformations and interhelical
and receptor-ligand contacts corresponding to the different
activation pathways stabilized by various agonists. These data
provide a basis for understanding D2L functional selectivity and
rationally discovering functionally selective D2 drugs.
Introduction
Functional selectivity is the phenomenon by which the
binding of a ligand to a receptor results in markedly different
levels of activation (or lack thereof) of one or several of the
signaling pathways linked to the targeted receptor. Although
this signaling bias runs counter to classic concepts of drug-
receptor mechanisms, it has become firmly established and
has been demonstrated for dozens of receptors (Urban et al.,
2007; Neve, 2009). As well as being heuristically interesting,
it is also generally appreciated that functionally selective
ligands with the “correct” bias may yield improved therapeu-
tic indices versus drugs that are “typical” agonists or antag-
onists (Mailman, 2007). It is generally believed that the
functionally selected properties of a ligand are a result of
the differential stabilization and/or induction of active
states of the target receptor that are associated with spe-
cific signaling pathways (Kenakin, 1995, 2007; Urban et
al., 2007). However, there has been little exploration of
how this may occur.
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One of the earliest demonstrations of functional selectivity
was with the dopamine D2 receptor (Lawler et al., 1994,
1999). In particular, studies with a series of relatively rigid,
conformationally restrained D2 ligands showed extreme bias
in signaling, in some cases as extreme as full agonist and
pure antagonist (Mottola et al., 1991, 2002; Kilts et al., 2002;
Gay et al., 2004). Thus, in Chinese hamster ovary (CHO) cells
expressing hD2L receptors, Gay et al. (2004) reported that
dinapsoline (DNS) was a full agonist at several functions
[e.g., fully inhibiting cAMP accumulation (AC) and fully
stimulating p44/p42 MAP kinase phosphorylation (MAPK)]
yet was a partial agonist at stimulating G protein-coupled
inward rectifying potassium channels. Conversely, dinoxy-
line (DNX) was a full agonist at all four effector pathways
(Gay et al., 2004). These data are noteworthy because there
are only subtle differences in the chemical structures of DNS
and DNX (see Fig. 1).
Subtle structural difference in a ligand may lead to func-
tional selectivity (Gay et al., 2004; Ryman-Rasmussen et al.,
2005). Thus, we hypothesized that modification of the D2L
receptor in regions where such ligands bind could be infor-
mative about the manner by which functionally selective
signaling occurs. The current experiments address this hy-
pothesis by studying the role of specific binding interactions
that occur between the D2L receptor and three rigid analogs,
dihydrexidine (DHX) (Lovenberg et al., 1989), DNS (Ghosh et
al., 1996), and DNX (Grubbs et al., 2004). These ligands were
originally designed as novel D1 agonists in which the acces-
sory phenyl ring was expected to confer both high D1 affinity
and high D1:D2 selectivity (Nichols, 1983; Charifson et al.,
1989; Mottola et al., 1996). All three compounds also unex-
pectedly had significant D2 affinity, leading to the discovery
of D2 functionally selective signaling for DHX and DNS (Kilts
et al., 2002; Mottola et al., 2002; Gay et al., 2004).
In the current study, computational approaches were used
to hypothesize specific binding interactions within each li-
gand-receptor complex. The affinity and functional proper-
ties of the probe and reference ligands was then assessed
using four distinct functional endpoints. The resulting data
are consistent with the hypothesis that subtle changes in
ligand-specific interactions induced by mutation of se-
lected amino acids of the receptor may stabilize and/or
induce certain receptor conformations that lead to func-






chromeno[4,3,2,-de]isoquinoline], and dihydrexidine [trans-10,11-
dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine] were
synthesized according to published procedures (Brewster et al., 1990;
Ghosh et al., 1996; Grubbs et al., 2004). Dopamine, quinpirole, 3-isobu-
tyl-1-methylxanthine, EDTA, dithiothreitol, sucrose, pepstatin A, leu-
peptin, PMSF, fetal bovine serum, and other standard chemical re-
agents were purchased from Sigma-Aldrich (St. Louis, MO) and Sigma/
RBI (Natick, MA). [3H]N-methylspiperone, [3H]arachidonic acid (or
[5,6,8,9,11,12,14,15-3H(N)]AA), and [35S]GTPS were purchased from
Amersham Biosciences Inc. (Chalfont St. Giles, Buckinghamshire, UK).
125I for cAMP assays was purchased from PerkinElmer Life and Ana-
lytical Sciences (Waltham, MA), and processed as described by Brown et
al. (2009). cAMP primary antibody was obtained from Dr. Gary Brooker
(George Washington University, Washington DC); secondary antibody,
rabbit anti-goat IgG, was purchased from Advanced Magnetics (Cam-
bridge, MA). HEPES buffer was purchased from Research Organics
(Cleveland, OH). Ham’s F-12, Opti-MEM, penicillin, streptomycin,
primers, and lipofectamine were purchased from Invitrogen (Carlsbad,
CA). Hygromycin B was purchased from Roche Applied Science (Indi-
anapolis, IN). Primary antibody to phospho-p44/p42 MAPK and second-
ary antibody, anti-rabbit horseradish peroxidase-conjugated, were pur-
chased from Cell Signaling Technology Inc. (Danvers, MA).
Molecular Biology and Cell Culture
CHO hD2L wild-type and mutant cells were maintained in Ham’s
F-12 media supplemented with 10% fetal bovine serum, 100 peni-
cillin-streptomycin, and 100 g/ml hygromycin. Mutant cell lines
were constructed using the pcDNA5/FRT plasmid obtained from
Invitrogen. After subcloning of the hD2L receptor into the plasmid,
point mutations were introduced using standard polymerase chain
reaction techniques. Stable transfections of point mutants into CHO
K1 cells were conducted using modifications of a previously pub-
lished protocol (Milligan, 1999). Throughout this article, the identi-
fication of the mutated amino acid residue will be made using uni-
versal notation proposed by Ballesteros and Weinstein (1995) in
























Fig. 1. Structures of probe ligands used in this study.
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located, and the second number pair is the location of the residue
under question relative to the most conserved residue for that helix.
The residues we studied (listed in both universal notation and abso-
lute position) were S5.42A (S193A), S5.43A (S194A), and S5.46A
(S197A).
Radioreceptor Assays
Membranes for radioreceptor assays were prepared by rinsing
cells with phosphate-buffered saline and then lysing with a solu-
tion containing 2 mM HEPES, 2 mM EDTA, 1 mM dithiothreitol,
1 g/ml pepstatin A, 0.5 g/ml leupeptin, and 0.05 g/ml PMSF.
Cell fragments were scraped, homogenized, and centrifuged at
30,000g for 30 min. After centrifugation, cell pellets were resus-
pended, homogenized, and placed into storage buffer (50 mM
HEPES, 0.32 M sucrose, 1 g/ml pepstatin A, 0.5 g/ml leupeptin,
and 0.05 g/ml PMSF) and stored at 80°C. Saturation binding
assays were conducted using protocols described previously (Gay
et al., 2004) but with varying concentrations of [3H]N-methyl-
spiperone to determine the Bmax and KD for each membrane prep-
aration (e.g., hD2L WT, hD2L S5.42A, etc.). Domperidone (10 M)
was used to define nonspecific binding. Competition binding as-
says also used [3H]N-methyl-spiperone.
Because these experiments incorporated detailed functional anal-
ysis including GTPS activation, we did not make use of a nonhy-
drolyzable GTP analog such as Gpp(NH)p to estimate the proportion
of receptors that were G protein-coupled. In retrospect, this might
have been useful and should be considered in future testing of the
hypotheses outlined under Discussion.
GTPS Assay
Measurement of [35S]GTPS binding was determined as described
previously (Shapiro et al., 2003), with nonspecific binding defined by
10 M unlabeled GTPS. Assay tubes contained 150 to 200 pM
[35S]GTPS, binding buffer (50 mM HEPES, 100 mM NaCl, 4 mM
MgCl2, 1 mM EDTA, 0.1% BSA, 0.1% ascorbic acid, pH adjusted to
7.4 with NaOH), 10 M GDP, and various concentrations of agonists
and/or antagonist. Membranes (approximately 100 g protein/ml)
were incubated with test compounds for 15 min at 30°C before
addition of [35S]GTPS. After an additional 30-min incubation, the
assay was terminated by filtration (Packard Filtermate 190 har-
vester; PerkinElmer Life and Analytical Sciences) with ice-cold wash
buffer (50 mM HEPES and 4 mM MgCl2, pH adjusted to 7.4 with
KOH), and radioactivity quantified by liquid scintillation spectrom-
etry (Packard TopCount NXT; PerkinElmer Life and Analytical
Sciences).
cAMP Accumulation Assay
Measurement of dopamine receptor agonist inhibition of forskolin-
stimulated cAMP accumulation was performed in whole-cell prepa-
rations as described previously (Gay et al., 2004). In brief, CHO cells
were seeded in 24-well plates at a density of 2.5  106 cells/well, and
grown for 48 h in Ham’s F-12 media supplemented with 10% fetal
bovine serum and 100 penicillin-streptomycin. Cells were preincu-
bated for 5 min before in fresh media (serum-free media containing
25 mM HEPES, 500 M 3-isobutyl-1-methylxanthine, and 0.1%
ascorbic acid) at 37°C. Assay medium then was aspirated, and fresh
assay medium containing forskolin and/or various concentrations of
the test compounds were added. The plates were incubated for 15
min at 37°C, and cells were rinsed with fresh assay medium and then
aspirated; the reaction was halted using 0.1 N HCl. The cAMP was
quantified using a modified radioimmunoassay described previously
(Harper and Brooker, 1975).
MAPK Assay
Measurement of dopamine receptor agonist stimulation of p44/p42
MAPK was performed in whole cell preparations by modifying a
previously published protocol (Versteeg et al., 2000). CHO cells were
seeded in 96-well plates at a density of 5  106 cells/well and grown
for 48 h in Ham’s F-12 media supplemented with 10% fetal bovine
serum at 37°C. Cells were serum-starved for 6 h before stimulation.
Appropriate drug dilutions of the test compounds were added to each
well at a volume of 100 l for 10 min. The reaction then was
terminated, and the cells fixed by aspirating the wells and adding
100 l of 4% formaldehyde PBS solution for 20 min. Cells were
washed three times with 100 l of wash buffer (0.1% Triton X-100/
PBS solution), followed by a 20-min incubation with 0.6% H2O2
Triton/PBS solution to quench endogenous peroxidases. After wash-
ing the cells three times again with wash buffer, and after a 1-h
incubation with 10% BSA in Triton/PBS solution (to block nonspe-
cific antibody binding), cells were incubated overnight (approxi-
mately 12 h) with a 1:250 dilution of PhosphoPlus p44/42 primary
antibody (Cell Signaling Technology) in the Triton/PBS solution (100
l) containing 5% BSA at 4°C. Cells were washed three times with
wash buffer for 5 min and then incubated with 100 l of horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody (1:100
dilution) with 5% BSA at room temperature for 1 h. Again, cells were
washed three times with wash buffer for 5 min and then twice with
PBS. Cells were then incubated with 50 l of an o-phenylenediamine
solution (0.4 mg/ml o-phenylenediamine, 17.8 mg/ml Na2HPO47H2O,
7.3 mg/ml citric acid, and 0.015% H2O2) for 15 min at room temperature
in the dark. The reaction was terminated by the addition of 25 l of 1 M
H2SO4 that causes a light- to dark-orange color change (A490–A650) that
is proportional to phosphorylation.
Arachidonic Acid Assay
Measurement of dopamine receptor agonist potentiation of ATP-
stimulated [3H]AA release was measured in whole-cell preparations
using modifications of a previously published method (Berg et al.,
1998). CHO cells were seeded in 24-well plates at a density of 5  105
cells/well and grown for 24 h in Ham’s F-12 media supplemented
with 10% fetal bovine serum at 37°C. Cells are serum-starved with
500 l of serum-free Ham’s F-12 containing 0.5 Ci/ml [3H]AA for 5 h
at 37° C. Ten-microliter aliquots were removed to compare with the
original tritiated loading media to determine the time course and
total cellular uptake of [3H]AA. Cells were washed three times for 5
min each with Hanks’ balanced salt solution containing 0.5% fatty
acid-free BSA and antagonists for respective wells (500 l/well/
wash). Cells then were incubated with agonists for 15 min with or
without ATP dissolved in Hanks’ balanced salt solution/BSA (ATP
being added last and in timed increments of 5 s between wells).
Data and Statistical Analysis
Data were analyzed using Prism 4.0/5.0 (GraphPad Software, San
Diego CA). Saturation analysis was conducted using a one-site bind-
ing model (Prism). Competition data used nonlinear regression and
a sigmoidal equation to determine IC50 and Emax values. The IC50
values were corrected for radioligand concentration and are reported
as corrected affinity values (K0.5) adjusted by the Cheng-Prusoff
equation for bimolecular interactions (Cheng and Prusoff, 1973) re-
gardless of Hill coefficient (nH). Intrinsic activity and potency esti-
mates were made from sigmoidal fits of dose response data using
Prism. Statistical analyses were conducted using SigmaStat 2.03
(Systat Software, Inc., San Jose, CA) or Instat 3 (GraphPad Soft-
ware), using algorithms specified with each experiment.
Computational Strategy
Homology Model of Human D2L Receptor. The human D2L
was modeled using three closely related GPCR crystal structures as
templates: the 2-adrenergic receptor (PDB ID: 2RH1); dopamine D3
receptor (PDB ID: 3PBL); and bovine rhodopsin (PDB ID: 1GZM).
Because of the distant homology and different transmembrane pack-
ing compared with the biogenic amine receptor crystals, the adeno-
sine receptor was not used as a template for modeling the D2L. The
disulfide-bonded cystines between extracellular loop 2 and TM3 were
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identified from sequence alignment with other class A GPCRs. The
homology model was predicted using the software MODELLER
(http://salilab.org/modeller/) (Fiser and Sali, 2003), followed by opti-
mization of polar residues and energy minimization.
Ligand Docking. The agonist structures were modeled using the
SCHRODINGER Maestro interface (Schrodinger LLC, Portland,
OR). The ligand structures were optimized, and partial changes were
calculated (QM, basis set 6-31G**) using the software Jaguar (Sch-
rodinger LLC). Multiple conformations of the ligands were generated
using Monte Carlo sampling (Macromodel, Maestro; Schrodinger
LLC), and these conformations were docked into the D2L receptor
model using Glide standard precision module of Maestro. During
docking, the van der Waals radii of both ligands and the receptor
were scaled by 0.5 to increase diversity of the docked poses. The
resulting ligand poses were clustered, and the top-ranking pose from
each cluster was chosen based on binding energy. The final bound
pose for each agonist was selected from these top ranking poses by
visual inspection.
Ligand-Induced Receptor Conformational Changes. The li-
gand-induced receptor conformational change method has been dis-
cussed in detail previously (Bhattacharya et al., 2008b, 2010). Here
we detail the steps of the method as applied to hD2L. We identified
that TM helices 3, 5, and 6 are in direct contact with all the agonists
and hence would undergo conformational changes as a result of
ligand binding. We performed simultaneous systematic spanning of
the rotational orientation of TM helices 3, 5, and 6 in 10° increment
with respect to the initial state. Although TM3, TM6 were rotated 50°,
TM5 was rotated from 50° to 20°. This process generated 968 recep-
tor conformations. For each conformation, the following steps were
performed.
• Optimization of all side-chain conformations using SCWRL 3.0
(http://dunbrack.fccc.edu/scwrl4/SCWRL4.php) (Canutescu and
Dunbrack, 2003).
• Conjugate gradient minimization of the potential energy of the
ligand in the field of the rest of protein fixed until convergence of
0.3 kcal/mol-Å root-mean-square deviation in force per atom is
achieved.
• Calculation of the ligand binding energy, defined as the difference
of the potential energy of the ligand with protein fixed and the
potential energy of the free ligand calculated in water using Gen-
eralized Born solvation method (Zamanakos, 2001).
• Interhelical and ligand-receptor hydrogen bonding using HB-
PLUS 3.0 (http://www.biochem.ucl.ac.uk/bsm/hbplus/) (McDonald
and Thornton, 1994). This generates a three dimensional binding
energy landscape in the rotational degrees of freedom of TMs 3, 5,
and 6.
• Identification of all the local minima in this landscape and sorting
of them by total number of interhelical hydrogen bonds (HB) and
ligand-receptor HB and then by binding energy. The final ligand
stabilized receptor structural model was selected based on low
binding energy and high number of HBs.
Results
Ligand Rationale. For these studies, we compared the
actions of the endogenous ligand dopamine and the prototyp-
ical D2 agonist quinpirole with those of DHX, DNS, and DNX.
The D2 functional selectivity of dihydrexidine in vitro is
consistent with both its D2 functional selectivity in situ (Kilts
et al., 2002; Mottola et al., 2002) and its lack of amphet-
amine-like behavioral actions (Darney et al., 1991), despite
being a full D1 and D2 agonist at the canonical signaling
pathway. Of particular importance for the present study is
the fact that dihydrexidine has a fused ring structure with no
rotatable bonds. This relatively rigid structure decreases the
degrees of freedom in interpreting data of the type this study
was designed to generate. The second important ligand used
was dinapsoline, another rigid compound that also has been
shown to have functionally selective properties with the D2
wild-type receptor (Gay et al., 2004). The third related ligand
was dinoxyline, a compound that differs from dinapsoline
only in an ether-methylene bridge substitution, a feature
hypothesized to influence receptor interactions in subtle, but
meaningful, ways. The structures of the eutomers of these
compounds are shown in Fig. 1. In all cases, the D2 affinity of
the distomer is at least 100-fold less than the eutomer at the
wild-type D2 receptor, and because of limited or unavailabil-
ity of pure eutomer, racemic mixtures were used for this
research. The reported K0.5 values are based on the concen-
tration of the racemate and were not corrected for the effects
of the distomer. The synthetic ligands had no functional
effect in any of these assays performed in wild-type CHO K1
cells not containing the D2L receptor. The D2 antagonist
domperidone (10 M) was tested against WT and all receptor
mutants; as expected, no functional activation was seen at
any endpoint tested. Domperidone completely blocked quin-
pirole activation of all effector endpoints with both WT and
mutant receptors.
Effect of S5.42A, S5.43A, and S5.46A Mutants on Re-
ceptor Expression and Antagonist Radioligand Bind-
ing. On the basis of the large body of data for aminergic
GPCRs and of the D2 receptor that elucidated many aspects
of the role of TM5 serines in interaction with ligands (Strader
et al., 1989; Cox et al., 1992; Mansour et al., 1992; Woodward
et al., 1996; Wiens et al., 1998; Shi and Javitch, 2002), we
chose to explore the effects of the TM5 serine residues
Ser5.42, Ser5.43, and Ser5.46 on the functional efficacy of the
above-mentioned ligands for various signaling pathways.
The hD2L WT, S5.42A, S5.43A, and S5.46A receptors were
expressed stably in CHO K1 cells and characterized by
TABLE 1
Competition binding data for 3H	N-methylspiperone sites at TM5 serine mutants
Values represent mean  S.E.M. The expression of these receptors was as follows: WT: KD, 0.58 nM; Bmax, 4.8 pmol/mg; S5.42A: KD, 0.59 nM; Bmax, 4.0 pmol/mg; S5.43A:
KD, 1.4 nM; Bmax, 20.7 pmol/mg; S5.46A: KD, 0.50 nM; Bmax, 2.3 pmol/mg.
Mutant
K0.5
WT S5.42A S5.43A S5.46A
nM
DNS 144  17 660  190 750  370 330  160
DNX 83  5 2700  990* 770  90 580  340
DHX 490  91 7400  1000* 2,600  50 1600  40
Quinpirole 365  6 1040  100 27,000  10,000* 2900  820
Dopamine 450  170 80,000  3000* 31,000  6000* 3500  1,500
* Significantly different from WT (P  0.05; one-way ANOVA and Tukey-Kramer Multiple Comparisons Test).
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means of saturation radioreceptor assays using [3H]N-meth-
ylspiperone. As is shown in Table 1 and Supplementary Fig.
1, these mutations had only slight effects on the KD, ranging
from 0.50 nM for S5.46A to 1.4 nM for S5.43A (WT 0.58 nM).
The expression level also was similar for the WT, S5.42A, and
S5.46A (2.3–4.0 pmol/mg of protein), whereas the S5.43A
expressed at a somewhat higher density (20.7 pmol/mg of
protein).
Effect of S5.42A, S5.43A, and S5.46A on Affinity of
Agonist Probe Ligands. The affinity for each probe ligand
was determined using competition radioreceptor assays ver-
sus [3H]N-methylspiperone in membranes from both WT and
mutant receptors. An apparent affinity constant, K0.5 (Table
1), was determined from experimental IC50 values corrected
for radioligand KD and concentration using the bimolecular
Cheng-Prusoff relationship (Cheng and Prusoff, 1973). Com-
petition binding studies also were conducted with several
structurally distinct antagonists to rule out gross structural
changes induced by the receptor (data not shown). Although
all of the antagonists had slightly decreased affinity (as
found for N-methylspiperone), the rank order of their affinity
was unchanged, consistent with the hypothesis that these
mutations caused no major changes to the overall receptor
structure.
Representative data for each agonist probe ligand at each
receptor are shown in Fig. 2 and summarized in Table 1. It
should be noted that although the differences between drugs
was not always statistically significant when comparing the
means (Table 1), the rank order was identical in each of the
experimental replicates. The differential effects that these
mutations had on the rigid probe ligands are striking. For
example, the S5.42A and S5.46A mutations caused a much
greater loss of affinity to DNX than to the structurally sim-
ilar DNS. These differential changes can be seen by compar-
ing the rank orders of affinity.
• WT: DNX 
 DNS 
 quinpirole  dopamine  DHX.






• S5.43A: DNS  DNX 
 DHX 

 quinpirole  dopamine.
• S5.46A: DNS 
 DNX 
 DHX 
 quinpirole  dopamine.
Effect of Mutations on Ligand-Induced GtpS Bind-
ing. An estimate of G protein turnover was conducted by
assessing the ligand-induced binding of the nonhydrolyzable
GTP analog [35S]GTPS (Fig. 3; Table 2). As has been re-
ported previously (Gay et al., 2004), DHX and DNS were
partial agonists at stimulating GTPS binding, a property
shared by DNX. The most remarkable finding in this exper-
iment related to S5.43A. As noted above, this mutation
caused a decrease in affinity of all of the ligands (Table 1; Fig.
2), yet the potency of the synthetic ligands in this assay was
either unaffected or actually increased (significant for DNX).
In addition, S5.43A actually increased the intrinsic activity
of DNS. Conversely, S5.42A and S5.46A tended to cause a
DNS





























































































Fig. 2. Competition binding of test
compounds with hD2L WT and mutant
receptors. Membranes were incubated
with [3H]N-methylspiperone as de-
scribed under Materials and Methods.
Analysis was conducted using nonlin-
ear regression and a sigmoidal equa-
tion to determine IC50 values, reported
as corrected affinity values (K0.5). As-
says were conducted in triplicate, and
data represent three to four indepen-
dent experiments. The mutations in the
symbol key of each panel are listed in







































































































































Fig. 3. GTPS turnover experiments of
test compounds with hD2L WT and mu-
tant receptors. Membrane fragments
were incubated for 15 min with varying
concentrations of test compounds until
reaching equilibrium. 0.2 nM [35S]GTPS
was then added for 30 min, and stimula-
tion was measured. Quinpirole and dopa-
mine had identical intrinsic activity in
WT cells, and the actions of quinpirole
were not affected by the mutations, hence
all of the data regarding quinpirole activ-
ity in WT cells. Analysis was conducted
using nonlinear regression and a sigmoi-
dal equation to determine IC50 values re-
ported in Table 2. Assays were conducted
in triplicate and data represent three to
four independent experiments. The mu-
tations in the symbol key of each panel
are listed in order of decreasing affinity.
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loss of both potency and intrinsic activity for all of the rigid
ligands. Quinpirole was relatively unaffected; no change was
evident in intrinsic activity and a significant decrease in
potency occurred at only S5.46A.
Functional Biochemical Differences Caused by
S5.42A. Measurement was conducted on the first of three
D2-linked pathways, agonist inhibition of forskolin-stimu-
lated cAMP accumulation in a whole-cell assay system, for
WT and S5.42A receptors (Fig. 4; Table 3; Supplemental Fig.
2). In the WT receptor, all dopamine agonists (DNS, DNX,
DHX, quinpirole, and dopamine) robustly inhibited forskolin-
stimulated cAMP accumulation. Conversely, inhibition of
cAMP accumulation with the S5.42A mutant was abolished
with all ligands tested except quinpirole. These data suggest
that S5.42A is critical for ligand-receptor–mediated confor-
mational changes associated with inhibitory actions of the
D2L receptor at cAMP accumulation (AC).
Measurement of a second pathway, agonist stimulation
and subsequent phosphorylation of the p44/p42 MAP kinase,
was then conducted in a whole-cell assay system for WT and
S5.42A receptors (Fig. 4; Table 3; Supplemental Fig. 3). In
the WT receptor system, all dopamine agonists (DNS, DNX,
DHX, quinpirole, and dopamine) fully activated MAPK.
S5.42A only minimally affected the actions of quinpirole
(EC50, 44 nM) compared with WT (EC50, 23 nM). Conversely,
the S5.42A mutation caused a complete loss of function at
this endpoint for DNS and DNX and a partial loss of intrinsic
activity for DHX.
Measurement of a third pathway, agonist-stimulated
[3H]arachidonic acid release, was conducted in a whole-cell
assay system for WT and S5.42A (Fig. 4; Table 3; Supple-
mental Fig. 4). The potency of quinpirole was decreased by
the S5.42A mutation (EC50, 223 versus 63 nM in WT), but
intrinsic activity was unaffected. Conversely, all of the other
ligands were inactive with the S5.42A receptor (see Table 3).
The MAPK and AA functional data provide strong evidence
that functional effects caused by the S5.42A mutation are
ligand-dependent and do not represent a general dysfunction
of the receptor.
Functional Biochemical Differences Caused by
S5.43A Mutant. The hypothesis that Ser5.43 is critical for
forming intrahelical H-bonds that stabilize the TM5  helix
TABLE 2
Potency of probe ligands in affecting GTPS binding
Values represent EC50  S.E.M. for three to four independent experiments conducted in triplicate.
Mutant
EC50
WT S5.42A S5.43A S5.46A
nM
DNS 290  70 — 135  25 —
DNX 550  30 — 69  17* 660  250
DHX 370  180 1300  410 92  28 6600  6200
Quinpirole 740  120 1700  860 203  5 7200  1900*
Dopamine 1700  1040 10,700  1500* 4300  1600 —























































































































































































































































































































































































































































Fig. 4. Ligand effects on intrinsic ac-
tivity of second-messenger pathways
of hD2L with mutations at S5.42A,
S5.43A, and S5.46A. Top row, ligand-
mediated inhibition of forskolin-stim-
ulated cAMP accumulation (AC). [For
the sake of comparison, in this panel,
greater receptor-mediated inhibition
is presented as a taller histogram bar
when it actually represents greater
inhibition.] Middle row, ligand-medi-
ated activation of p44/p42 MAPK.
Bottom row, ligand-mediated potenti-
ation of [3H]arachidonic acid release.
Note that agonists inhibit AC but
stimulate MAPK and AA release.
Data are representative of Emax val-
ues for three to five independent ex-
periments conducted in triplicate. ,
p  0.05 (one-way ANOVA, post hoc
Dunnett’s). , p  0.05 (Kruskal-
Wallace one-way ANOVA, post hoc
Dunn’s).
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was tested using functional profiling as summarized in Fig. 4
and Table 3. We hypothesized that mutation of S5.43A would
have minimal effect on intrinsic activity at all endpoints
measured with our test ligands. In support of that hypothe-
sis, S5.43A had no effect on AC inhibition versus WT, al-










 DHX (see Table 3
for EC50 values)].
The MAPK data are shown in Fig. 4, Table 3, and Supple-
mental Fig. 3. All of the test ligands (DNS, DNX, DHX,
quinpirole, and dopamine) fully activated MAPK in both WT
and the S5.43A mutant, although changes in rank order of
potency were observed [WT: dopamine  quinpirole 
DNX 
 DNS 





 DNX (see Table 3 for EC50 values)].
The S5.43A mutation had dramatic effects on agonist stim-
ulated [3H]arachidonic acid release (Fig. 4; Table 3; Supple-
mental Fig. 4). With the mutant receptor, quinpirole and
DNX were minimally affected, but activity of the other li-
gands was lost. It is noteworthy that the structurally similar
ligands DNS and DNX were affected oppositely with S5.43A.
These data indicate that the effects of the S5.43A mutation
were seen primarily on one function (AA), but not on two
others (AC, MAPK), at which the full agonist activity at the
WT receptor was maintained.
Functional Biochemical Differences Caused by
S5.46A. Ser5.46 is the TM5 serine residue located deepest in
the binding pocket of hD2L. The S5.46A mutation did not
affect the inhibition of AC by quinpirole, whereas none of the
other ligands retained activity. In a similar fashion, at both
MAPK and AA release, the activity of DNS, DNX, DHX, and
dopamine were absent with the S5.46A mutant. Quinpirole
maintained its intrinsic activity, but had modest loss of po-
tency (5- to 8-fold) at both functions.
Discussion
The rigid ligands used here were developed as D1 agonists
but were previously shown also to be functionally selective D2
ligands both in heterologous systems (Kilts et al., 2002; Gay
et al., 2004) and in situ (Kilts et al., 2002; Mottola et al.,
2002). They have atypical behavioral properties expected of
canonical D1:D2 agonists (Darney et al., 1991; Smith et al.,
1997; Gulwadi et al., 2001). Thus, these ligands provide
useful probes for our studies, and resulting hypotheses may
explain novel actions of these compounds in vivo.
Table 4 provides a nonquantitative summary of this study
that will permit easier integration of these complex data. The
S5.46A mutation caused a total loss of intrinsic activity for
dopamine, dihydrexidine, dinapsoline, and dinoxyline but
left quinpirole’s intrinsic activity unaffected, suggesting that
S5.46A did not disrupt the signaling ability. S5.43A mutation
did not markedly affect the intrinsic activity of quinpirole at
any function or affect the activity of DNX at any function, yet
completely eliminated intrinsic activity for dopamine, dihy-
drexidine, and dinapsoline at AA release, but not other func-
tions. Finally, S5.42A did not affect the intrinsic activity of
quinpirole, but with one exception (DHX at MAPK) elimi-
nated the intrinsic activity of dopamine and the rigid ligands.
Functional selectivity also can be expressed as large and
differential changes in potency (Gay et al., 2004) as shown in
Table 4. A recent report showed that H6.55 mutations of the
D2L can abolish the bias of some functionally selective li-
gands (Tschammer et al., 2011), but the current study dem-
onstrates that bias in a single function also can be introduced
by a point mutation (Fig. 4).
Strengths and Weaknesses of this Experimental Sys-
tem. It is now realized that GPCR functional selectivity may
not only involve differential activation of G protein hetero-
trimers, but also many other interactors (Urban et al., 2007).
Thus, even in the same cell, the same receptor may be in-
TABLE 3
Effect of serine mutations on functional potencies of probe ligands
Values represent EC50  S.E.M. for three to four independent experiments conducted in triplicate.
Ligand
EC50
WT S5.42 S5.43A S5.46
nM
Dopamine
AC 46  22 N.A. 19  3* N.A.
MAPK 28  7 N.A. 114  40* N.A.
AA-release 49  26 N.A. N.A. N.A.
Quinpirole
AC 16  6 7.8  1.4 3  1 54  11
MAPK 26  5 44  12 26  11 193  28
AA-release 63  12 223  67* 35  27 292  16*
DNX
AC 5.6  0.3 N.A. 36  17 N.A.
MAPK 27  17 N.A. 2,100  1,300 N.A.
AA-release 101  12 N.A. 40  18* N.A.
DNS
AC 193  63 N.A. 119  48 N.A.
MAPK 72  68 N.A. 155  9 N.A.
AA-release 340  180 N.A. N.A. N.A.
DHX
AC 93  10 N.A. 125  28 N.A.
MAPK 31  105 69  6.1 400  130 N.A.
AA-release 395  119 N.A. N.A. N.A.
N.A., no activity.
* Significantly different from WT (P  0.05; one-way ANOVA and Tukey-Kramer multiple comparisons test).
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volved in different “signalsomes,” and a measured endpoint
may be dependent on activity of two or more signalsomes.
Although it may seem desirable to have a totally defined
system in which to study different ligand-induced/stabilized
states, this is technically difficult, and no available system
recapitulates the characteristics seen consistently in situ and
in single native cells.
Although we assume that mutation-induced functional se-
lectivity is a consequence largely of alterations to the ligand-
receptor interactions, it is possible that ligand-independent,
mutation-induced alterations in the signalsome itself are
involved. Two lines of evidence suggest this is not a major
factor here. The reference ligand quinpirole has markedly
different predicted docking poses compared with the D2L
receptor. In our assays, quinpirole-induced functional activ-
ity was similar in mutant and WT receptors, suggesting that
functionally selective signaling of rigid ligands is not due
simply to disruption of D2 signaling. Moreover, in the current
studies, the effects on intrinsic activity were often dramatic
(e.g., 100% or 0% intrinsic activity), but if differential
changes were occurring via two alternate routes, partial ago-
nism might have been expected.
This raises an ancillary point. The S5.43A line had a much
higher receptor expression than the WT, S5.42A, or S5.46A
lines (Table 1), suggesting that the failure to find partial
agonism is a receptor reserve artifact. Yet partial agonism at
GTPS binding, uncorrelated with receptor expression, was
seen for all three rigid ligands. Indeed, the high expressing
S5.43A increased the potency of DNX in stimulating GTPS
binding, yet the same mutation markedly decreased DNX
potency at adenylate cyclase. Thus, although receptor re-
serve may have influenced these results, the effect was prob-
ably minor. In the case of S5.43A, the mutation caused a
major disruption only of a single function, and only for some
ligands. Together, this suggests that the functional effects
reflect alterations in ligand-receptor interactions and not
gross disruption of receptor function.
Computational Analysis. As noted above, none of the
mutations affected quinpirole activation, possibly because
the full agonists (quinpirole, DA, DNS, DNX, and DHX)
stabilize an ensemble of receptor conformations that show
coupling affinities different from those of downstream pro-
teins (Vaidehi and Kenakin, 2010). To test this hypothesis,
we computed the binding energy (BE) landscapes of the ago-
nists and D2L using the computational method of ligand-
induced receptor conformational change that has been vali-
dated for prediction of activation of rhodopsin (Bhattacharya
et al., 2008b) and 2-adrenergic receptor (Bhattacharya et
al., 2008a; Bhattacharya and Vaidehi, 2010). As seen in
Fig. 5C, the BE landscapes of dopamine shows two distinct
minima (agonist states 1 and 2). The BE landscape of the
other agonists are qualitatively similar (Supplemental Fig.
5). Small movements of TM3 and a counterclockwise rotation
of TM5 (from the extracellular side) that brings Ser5.43
closer to the binding pocket characterize both minima. The
difference between the two agonist-stabilized receptor con-
formations comes from TM6 movement. In receptor state 1,
movement of TM6 brings His6.55 closer to TM5, whereas in
state 2, TM6 movement brings His6.55 closer to TM7.
The agonist-preferred receptor conformations are stabi-
lized by both interhelical and receptor-ligand contacts.
Ser5.42 makes a hydrogen bond (HB) with the catechol hy-
droxyl groups of DA, DNS, and DNX (m-OH of DA, p-OH of
DNS, DNX; Fig. 5, B and E) in both agonist states 1 and 2.
TABLE 4
Qualitative summary of effects of mutations on probe ligands relative to WT.
Assay DHX DNS DNX QP DA
S5.42A
Binding 22 2 22 n 222
GTPS (EC50) n ID ID 7 2
AC (EC50) ID ID ID 1 ID
MAPK (EC50) m ID ID 7 ID
AA (EC50) ID ID ID n ID
GTPS (Emax) 22 222 22 7 22
AC (Emax) 222 222 222 7 222
MAPK (Emax) 22 222 222 2 222
AA (Emax) 222 222 222 22 222
S5.43A
Binding 2 2 2 222 222
GTPS (EC50) m m 1 m n
AC (EC50) 7 7 2 2 7
MAPK (EC50) 7 7 222 7 n
AA (EC50) ID ID n n ID
GTPS (Emax) 7 11 7 7 7
AC (Emax) 7 7 7 7 7
MAPK (Emax) 7 7 7 7 m
AA (Emax) 222 222 2 2 222
S5.46A
Binding 7 n 2 2 2
GTPS (EC50) 22 ID 7 22 2
AC (EC50) ID ID ID m 2
MAPK (EC50) ID ID ID 2 2
AA (EC50) ID ID ID 2 2
GTPS (Emax) 22 222 222 7 222
AC (Emax) 222 222 222 7 222
MAPK (Emax) 222 222 222 7 222
AA (Emax) 222 222 222 n 222
1, positive effect (i.e. decreased K0.5, decreased EC50, or increased Emax);7, minimal or no effect;2, detrimental effect (i.e. increased K0.5, increased EC50, or decreased
Emax); n, trend downward; m, trend upward; ID, indeterminable. 2  5- to 9-fold; 22  10- to 50-fold; 222  
50-fold; QP, quinpirole.
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This HB is missing in the DHX-bound structure (distance,
5.8Å), and therefore Ser5.42 contributes toward the stability
of the receptor active states of DA, DNS, and DNX, but to a
lesser extent for DHX. This is in agreement with the func-
tional selectivity profile of the S5.42A mutant, which com-
pletely abolishes activation of all pathways for all the ago-
nists except DHX and quinpirole, which still maintains
partial activity toward the MAPK pathway. In conjunction
with the predicted DHX bind site, this suggests that Ser5.42
does not form an HB with DHX in the MAPK-specific D2L
conformation. The lack of HB with Ser5.42 could be compen-
sated by stronger HB of DHX with the other two serines or
tighter aromatic contact between the agonist and the pheny-
lalanines on TM5 and TM6. This is not clear, however, from
the models. Thus, S5.42A has less drastic effect on DHX-
mediated MAPK activation.
In contrast to Ser5.42, the effect of Ser5.43 is more path-
way-specific. In the activation assays, the S5.43A mutant
only affected the AA pathway, whereas the other two path-
ways were unaffected for all agonists. For the AA pathway,
S5.43A abolished the intrinsic activity of DA, DNS, and DHX
and retained partial activity for DNX and quinpirole. In our
model, the receptor/agonist state 1 is stabilized by an HB
between Ser5.43 and His6.55 (Fig. 5B). In contrast, the re-
ceptor/agonist state 2 is stabilized by the HB between
His6.55 and Tyr7.35 (Fig. 5A). Thus our model, in conjunc-
tion with the results from the S5.43A mutant, indicates that
agonist state 1 may represent the receptor conformation that
mediates AA activation, whereas slightly different agonist
state 2 corresponds to the cAMP and MAPK activation, al-
though this hypothesis will require further experimentation
to test. In the DNX- and quinpirole-bound structures, the
side chain of His6.55 is proximal to the ether oxygen of DNX
and imidazole nitrogen of quinpirole, respectively. Thus, in
the S5.43A mutant, DNX and quinpirole can stabilize agonist
state 2 by forming HB with His6.55, whereas the other li-
gands (DA, DNS, DHX) that lack the polar motifs of DNX and
quinpirole cannot form this HB and hence cannot stabilize
state 1. These ligands require Ser5.43 to stabilize agonist
state 1 and thus lose AA activity in the S5.43A mutant. This
explains the insensitivity of S5.43A mutation toward DNX
and quinpirole-mediated AA activation.
S5.46A eliminates activation of the three pathways for all
agonists except quinpirole. In our agonist-stabilized model of
the D2 receptor, Ser5.46 forms a HB with Thr3.37 that sta-
bilizes agonist states 1 and 2 (Fig. 5). Thus mutating Ser5.46
to Ala destabilizes both the active states and abolishes activ-
ity of all the three pathways. Among the agonists studied
here, quinpirole shows a different activation profile com-














Fig. 5. Stabilization of multiple recep-
tor conformations (agonist states 1
and 2) by the D2 agonists. A, binding
site of DA in agonist state 2; B, bind-
ing site of DA in agonist state 1; C, BE
landscape of DA showing the different
agonist stabilized states; D, binding
site of DHX in agonist state 1; E, bind-
ing site of DNX in agonist state 1; F,
binding site of quinpirole in agonist
state 1. The red dotted lines represent
HB contacts. In the quinpirole bound
receptor, the moieties involved in sta-
bilizing the active states are shaded.
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activation assays, none of the serine mutations affected quin-
pirole-mediated D2 activation. Unlike the catechol agonists,
the nitrogen atoms on the imidazole of quinpirole are distant
from the serine residues on TM5, precluding the strong HB
with the serines in the agonist-stabilized states. This ex-
plains the insensitivity of the serine mutations toward quin-
pirole-mediated D2 activation. To understand the mechanism
of quinpirole activation, comparison of the interactions in the
ligand-binding pockets in both the inactive and agonist-sta-
bilized conformations showed that the n-propyl group of
quinpirole is buried deep into the binding pocket, allowing
direct contact with Trp6.48. The steric interaction could in-
duce a change of rotamer of the Trp6.48 side chain, which in
turn creates a steric clash with the side chain of Phe5.47 (Fig.
5F). To relieve the clash between Trp6.48 and Phe5.47, TM5
rotates counterclockwise, leading to the activation of the
receptor. Thus, Trp6.48 and Phe5.47 form an aromatic switch
that stabilizes the active states of quinpirole-bound hD2L.
Our model also suggests that His6.55 is important for quin-
pirole-mediated AA activation, because the HB between
quinpirole and His6.55 contributes to the stability of agonist
state 1.
Differences in the agonist stabilized receptor conforma-
tions could lead to functional selectivity in the D2L receptor.
Selective conformational stabilization by structurally dis-
tinct agonists was reported in 2-adrenergic receptor (Gha-
nouni et al., 2001; Swaminath et al., 2005). Here we find that
the three serine residues on TM5 interact differently with the
agonist to stabilize distinct D2L conformations for all agonists
except quinpirole. The Ser5.46–Thr3.37 HB stabilizes the
active state conformations of TM5, making Ser5.46 critical
for all three activation pathways. In contrast, Ser5.43 stabi-
lizes only one of the active states (AA pathway) by forming
HB with His6.55. S5.42A shows different effects on the dif-
ferent agonists (less effect on DHX-MAPK activation) de-
pending on the strength of the HB with various agonists.
Besides the serines, the residue His6.55 is predicted to be
important for the functionality of the D2 receptor, and data to
this effect were recently reported (Tschammer et al., 2011).
In -adrenergic receptors, the residue in the analogous posi-
tion of His6.55 (Asn6.55) has been shown to be important for
agonist activity. In the 2-adrenergic receptor, the N6.55L
mutation reduced the activity of norepinephrine (Wieland et
al., 1996). In the agonist bound crystal structures of the
1-adrenoreceptor (Warne et al., 2011), Asn6.55 forms an HB
with Ser5.43 similar to the predicted agonist-bound struc-
tures of the D2. In this work, His6.55 is predicted to stabilize
the D2 conformation responsible for AA activity by forming
HB with Ser5.43 and polar groups of quinpirole and DNX.
Unlike the serine mutations, which affect only the agonists
with catechol motif, the H6.55A mutation is predicted to
affect the activation of all agonists studied here, including
quinpirole. The model of D2 activation that emerges from this
work is summarized in Fig. 6. Although the computational
model presented here explains the differences between AA
versus cAMP/MAPK pathways, we attribute changes in func-
tional selectivity to ligand-receptor interactions, but neglects
effects on receptor-protein interactors. Thus, functional se-
lectivity can be engendered by mutations that perturb arres-
tin binding (Lan et al., 2009a; Lan et al., 2009b). Nonethe-
Fig. 6. Model of functional selectivity
in hD2L. The schematics show the re-
ceptor conformations corresponding to
the different activation pathways sta-
bilized by various agonists and the in-
terhelical and receptor-ligand con-
tacts looking from the extracellular
side: A, cAMP/MAPK activation by li-
gands DA, DNS, DNX (agonist state 2
in Fig. 5). B, AA activation by DA,
DHX, DNS (agonist state 1 in Fig. 5).
C, AA activation by DNX. D, mecha-
nism of activation by quinpirole for all
three pathways. The orientation of
TM6 where His6.55 faces TM5 corre-
sponds to the AA pathway, whereas
His6.55 facing TM7 represents cAMP/
MAPK activation.
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less, our data demonstrate that ligand-receptor interactions
can be a determinant of signaling bias, and the one clearly
most relevant to drug discovery.
Conclusions
Antagonists were essentially unaffected by these TM5 ser-
ine mutations because their binding to the D2 receptor, un-
like that of agonists, is less dependent on interactions with
these residues. The effects on the binding of these agonist
ligands also were largely predictable by existing molecular
models, whereas these mutations caused patterns of effects
on the functional activity of the probe ligands not directly
predictable from binding. One hypothesis is that ligands can
cause receptor populations to shift between groups of discrete
active states that are linked to specific signaling pathways.
Alternatively, each ligand may induce a discrete range of
conformational changes that affect, in a graded fashion,
whether specific signaling pathways are activated. At pres-
ent, the former hypothesis is one that has been largely fa-
vored and is the one that would explain the constitutive
activity often seen in cellular systems. In any event, the
ability to form and test hypotheses about how such changes
occur can be heuristically interesting but also may lead to
structure-based discovery of novel functionally selective
ligands.
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